OpenAI acquires Orchestra Bio, an AI biotech software startup
OpenAI has acquired Orchestra Bio, a four-year-old startup that built AI agents for biotech operations, integrating it into its life sciences research platform Rosalind.
What happened
OpenAI announced on Tuesday the acquisition of Orchestra Bio, which had raised approximately $20 million from investors including Andreessen Horowitz, Atria, and 8VC. Orchestra develops AI agents that assist biotech companies with drug discovery operations, including financial tracking and clinical trial scheduling. OpenAI is integrating Orchestra's team and technology into Rosalind, its AI model for life sciences research, and the Rosalind Workbench tool, which helps researchers plan experiments and analyze results. OpenAI has already secured major customers for Rosalind, including Moderna and Novo Nordisk.
Context
The acquisition reflects a broader strategy by major AI labs—OpenAI and Anthropic—to build specialized software for large industries, particularly pharmaceuticals. This move represents a consolidation within the biotech AI space, where startups have faced ongoing risk that large AI labs could enter the market as competitors. By acquiring Orchestra rather than competing with it, OpenAI is adding engineering talent and existing software capabilities to strengthen its life sciences offerings.